Document Detail


An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
MedLine Citation:
PMID:  15316165     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM: Androgenetic alopecia (AGA) is undoubtedly the most common form of hair loss in males. It is a condition which may cause cosmetic and psychosocial problems in androgen-dependent cases. In this open, randomized and comparative study we evaluated the efficacy of oral finasteride and 5% topical minoxidil treatment for 12 months in 65 male patients with mild to severe AGA. METHODS: We randomly assigned 40 (61.53%) patients to receive 1 mg/day oral finasteride for 12 months, and 25 (38.47%) patients applied 5% topical minoxidil solution twice daily for 12 months. RESULTS: There were no significant differences between the 2 groups considering age, age of onset of hair loss, family history and type of hair loss (p > 0.05). In the clinical evaluation at the endpoint of treatment, the clinical cure rates (i.e. increased intensity of hair) were 80% (32/40) for the oral finasteride group and 52% (13/25) for the 5% topical minoxidil group. Encountered side effects were all mild, and there was no need to stop the treatment. In the group given oral finasteride, side effects were noted in 7 patients: 6 patients suffered from loss of libido, and 1 patient had an increase in other body hairs; irritation of the scalp was seen in 1 patient in the group administered 5% minoxidil. These adverse events disappeared as soon as the treatment was stopped. The laboratory data on both drug groups did not show any statistically or clinically significant intragroup changes from baseline values to the endpoint (p > 0.05), except the level of serum total testosterone which was increased, and free testosterone and serum prostate-specific antigen in the finasteride group which were statistically decreased from baseline values to the endpoint (p < 0.05). CONCLUSION: In this comparative study of systemic finasteride and topical minoxidil, it was concluded that both drugs were effective and safe in the treatment of mild to severe AGA, although oral finasteride treatment was more effective (p < 0.05). Adverse events were not considered important either, and these side effects disappeared as soon as the treatment was stopped.
Authors:
Ercan Arca; Gürol Açikgöz; Halis Bülent Taştan; Osman Köse; Zafer Kurumlu
Related Documents :
8983555 - Absorbable skin graft staples: a clinical trial using graftac-x.
11182045 - Topical biafine and lipiderm for the prevention of radiation dermatitis: a randomized p...
23775205 - Outcome of intubate surfactant rapidly extubate (insure): an indian experience.
10225735 - Immunoadsorption for the treatment of bullous pemphigoid.
21336155 - A 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost...
24035045 - Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-an...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  209     ISSN:  1018-8665     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2004  
Date Detail:
Created Date:  2004-08-18     Completed Date:  2004-12-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  117-25     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Gülhane Military Medical Academy, School of Medicine, Etlik-Ankara, Turkey. earca@gata.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Administration, Topical
Adolescent
Adult
Alopecia / diagnosis,  drug therapy*
Analysis of Variance
Dose-Response Relationship, Drug
Drug Administration Schedule
Finasteride / administration & dosage*
Follow-Up Studies
Humans
Male
Middle Aged
Minoxidil / administration & dosage*
Patient Satisfaction
Probability
Reference Values
Statistics, Nonparametric
Treatment Outcome
Chemical
Reg. No./Substance:
38304-91-5/Minoxidil; 98319-26-7/Finasteride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early cutaneous alterations in experimental sepsis by Pseudomonas aeruginosa.
Next Document:  Rapid clearance of psoriatic skin lesions induced by topical cyclopamine. A preliminary proof of con...